The AJMC® Medicare compendium is a comprehensive resource for clinical news and expert insights on issues that affect Medicare beneficiaries with a focus on polypharmacy, reimbursement challenges, and other topics related to seniors.
April 4th 2025
This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.
Study Contradicts Other Research About Potentially Inappropriate Medications Among Older Adults
September 22nd 2021The current study found that those prescribed potentially inappropriate medications were actually less likely to revisit the emergency department within 30 days, in contrast to prior work.
Read More
BPCI Model Not Equipped to Tackle Reform of SNF Spending, Researchers Find
September 17th 2021The study found that BPCI Model 3, which held postacute facilities accountable for costs of care, was not associated with payment reductions or changes in other quality and selection metrics among skilled nursing facilities.
Read More
Consumer Data Transparency Is More Important Than Ever as the Battle Against COVID Rages On
September 6th 2021On January 1, CMS implemented the Hospital Price Transparency final rule, but by July, it was clear that many hospitals were noncompliant. Even with a proposed rule for penalties, requirements still only fall on certain parts of the health care industry.
Read More
What We’re Reading: 70% of US Vaccinated; CMS Payment Rules Released; Alcohol Consumption and Cancer
August 3rd 2021Seventy percent of Americans have received at least 1 dose of a COVID-19 vaccine; CMS releases payment rules for fiscal year 2022; alcohol linked to over 700,000 new cancer diagnoses in 2020.
Read More
MA Primary Care Payment Models Influenced Telemedicine Usage During the Pandemic, Research Shows
July 16th 2021Larger primary care practices in downside risk–only payment models and capitation saw the highest telemedicine utilization rates by their patients enrolled in Medicare Advantage (MA) plans.
Read More
Trends in Medicare Part D Coverage of Generics With Equivalent Brand-Name Drugs
High-tier generic drug placement in Medicare Part D has increased over time, but it may be related to a drug’s clinical profile and availability of substitutes rather than preferred brand-name drug coverage.
Read More
How Biogen’s Aduhelm Approval Marks a Precipitous Turning Point for the FDA
July 14th 2021A string of controversies surrounding the approval of Biogen's Alzheimer disease drug aducanumab (Aduhelm) has not only called into question the independent nature of the FDA, but puts both providers and patients in a challenging position when it comes to deciding whether or not to prescribe or take the treatment.
Read More